Press releases
- RemeGen Showcases Research Results at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, Highlighting Its Prolific Innovation in Global Cancer Treatment
- RemeGen Reports Proof-of-Concept Phase I/II Clinical Study Results for Self-Developed, Potential First-in-Class Antibody-Drug Conjugate RC88
- RemeGen Completes Patient Enrollment in Two Phase III Clinical Trials Using Telitacicept for Treatment of IgA Nephropathy and Primary Sjögren's Syndrome
- RemeGen Celebrates World Lupus Day 2024 with Increased Lupus Visibility through Vital Knowledge Sharing
- RemeGen's Telitacicept (RC18) Granted Fast Track Designation by United States FDA for Treatment of Primary Sjögren's Syndrome
More ▼
Key statistics
On Monday, RemeGen Co Ltd (REGMF:PKC) closed at 4.00, -2.44% below its 52-week high of 4.10, set on Dec 22, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.00 |
---|---|
High | 4.00 |
Low | 4.00 |
Bid | -- |
Offer | -- |
Previous close | 4.00 |
Average volume | -- |
---|---|
Shares outstanding | 544.33m |
Free float | 307.55m |
P/E (TTM) | -- |
Market cap | 22.34bn HKD |
EPS (TTM) | -3.02 HKD |
Data delayed at least 15 minutes, as of May 20 2024 14:30 BST.
More ▼